Clinical Trial Update: A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia [Phase 2]

View source ↗

Summary

The document reports the completion of a 4-week, randomized, placebo-controlled, double-blind Phase 2 trial evaluating HS-25 for efficacy and safety in adults w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• HS-25

Snippet

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. | Conditions: Primary Hypercholesterolemia | Phase 2 | Status: COMPLETED